FDA Endorses JOURNAVX™ (Suzetrigine): A Peripheral Sodium Channel Blocker Redefining Acute Pain ManagementThe FDA has approved JOURNAVX™ (suzetrigine), Vertex Pharmaceuticals groundbreaking oral non-opioid therapy for moderate-to-severe acute pain. This marks the first new class of pain medication since Celebrex in 1998, targeting NaV1.8, a sodium channel critical for peripheral pain signaling.
on
February 4, 2025
Pune's GBS Outbreak: 158 Cases and Counting, WHO on the Ground !In a significant surge of Guillain-Barré Syndrome (GBS) in Pune, the total number of patients has now reached 158, with nine new cases reported on Sunday. Although no additional deaths have been recorded, bringing the toll to five, health authorities remain on high alert. Notably, patients on ventilator support decreased from 28 to 21, and ICU admissions dropped from 83 to 48. Hospitals report good recoveries, with 38 people discharged so far.
on
February 3, 2025
FDA Greenlights Novel NSAID/Triptan Combo for Rapid Migraine ReliefThe US Food and Drug Administration (FDA) has approved Symbravo (rizatriptan/meloxicam), a novel oral combination therapy for the acute treatment of migraine with or without aura in adults. Developed by Axsome Therapeutics, Symbravo leverages rapid absorption technology to target multiple migraine pathways, offering rapid and sustained relief.
on
February 1, 2025
India’s MedTech Boom: A Beacon of Growth and PossibilityIndia’s medical technology sector is witnessing unprecedented growth, driven by robust government policies, rising demand, and thriving exports. Minister of State for Health Anupriya Patel highlighted that the current industry size of USD 14 billion could potentially exceed USD 30 billion by 2030. With 100 per cent FDI allowed through the automatic route, international investments have surged, bolstering the sector’s expansion.
on
January 31, 2025
Supreme Court Scraps Domicile Quotas: PG Medical Admissions to Be Strictly Merit-BasedIn a landmark judgment, the Supreme Court has struck down domicile-based reservations in postgraduate (PG) medical courses, calling them a breach of the Constitution’s equality clause under Article 14. The three-judge bench emphasised that "we are all domiciles in the territory of India. We are all residents of India."
on
January 30, 2025

Featured

FDA Endorses JOURNAVX™ (Suzetrigine): A Peripheral Sodium Channel Blocker Redefining Acute Pain Management
Pune's GBS Outbreak: 158 Cases and Counting, WHO on the Ground !
FDA Greenlights Novel NSAID/Triptan Combo for Rapid Migraine Relief
India’s MedTech Boom: A Beacon of Growth and Possibility
Supreme Court Scraps Domicile Quotas: PG Medical Admissions to Be Strictly Merit-Based

Participate in India’s healthcare revolution

Create ABHA & store all your medical records with Eka care (Govt of India ABDM approved PHR app)

Create ABHA ID

Popular topics

#

newfeature

#

Partnership

#

funding